Sex Differences in TB Clinical Presentation, Drug Exposure, and Treatment Outcomes in India.

Autor:	Deshmukh S; Byramjee Jeejeebhoy Government Medical College-Johns Hopkins University Clinical Research Site, Pune, India; Johns Hopkins India, Pune, India., Sane M; Byramjee Jeejeebhoy Government Medical College-Johns Hopkins University Clinical Research Site, Pune, India; Johns Hopkins India, Pune, India., Gaikwad S; Byramjee Jeejeebhoy Government Medical College, Pune, India., Sahasrabudhe T; Dr. D.Y. Patil Medical College, Hospital & Research Centre, Dr. D. Y. Patil Vidyapeeth, Pune, India., Barthwal M; Dr. D.Y. Patil Medical College, Hospital & Research Centre, Dr. D. Y. Patil Vidyapeeth, Pune, India., Lokhande R; Byramjee Jeejeebhoy Government Medical College, Pune, India., Raskar S; Byramjee Jeejeebhoy Government Medical College-Johns Hopkins University Clinical Research Site, Pune, India; Johns Hopkins India, Pune, India., Kagal A; Byramjee Jeejeebhoy Government Medical College, Pune, India., Dharmshale S; Byramjee Jeejeebhoy Government Medical College, Pune, India., Pradhan N; Byramjee Jeejeebhoy Government Medical College-Johns Hopkins University Clinical Research Site, Pune, India; Johns Hopkins India, Pune, India., Gupte A; Johns Hopkins University School of Medicine, Baltimore, MD., Alfarisi O; Johns Hopkins University School of Medicine, Baltimore, MD., Gupta A; Johns Hopkins University School of Medicine, Baltimore, MD., Dooley KE; Johns Hopkins University School of Medicine, Baltimore, MD., Gupte N; Byramjee Jeejeebhoy Government Medical College-Johns Hopkins University Clinical Research Site, Pune, India; Johns Hopkins India, Pune, India; Johns Hopkins University School of Medicine, Baltimore, MD., Golub JE; Dr. D.Y. Patil Medical College, Hospital & Research Centre, Dr. D. Y. Patil Vidyapeeth, Pune, India., Mave V; Byramjee Jeejeebhoy Government Medical College-Johns Hopkins University Clinical Research Site, Pune, India; Johns Hopkins India, Pune, India; Johns Hopkins University School of Medicine, Baltimore, MD. Electronic address: vidyamave@gmail.com.
Jazyk:	angličtina
Zdroj:	Chest [Chest] 2023 Apr; Vol. 163 (4), pp. 778-789. Date of Electronic Publication: 2022 Sep 26.
DOI:	10.1016/j.chest.2022.09.024
Abstrakt:	Background: The role of sex differences in clinical presentation, TB drug pharmacokinetic variables, and treatment outcomes is unclear. Research Question: What is the effect of sex on TB disease severity, drug exposure, and treatment outcome? Study Design and Methods: This study was a prospective cohort study conducted in India. It assessed TB disease severity; risk of unfavorable treatment outcomes (failure, recurrence, and death) according to sex; and risk factors for unfavorable outcomes stratified according to sex. Effects of sex on the pharmacokinetic variables (maximum concentration and area under the curve) of rifampicin, isoniazid, and pyrazinamide were estimated by using noncompartmental analyses. Results: Of 1,541 people with microbiologically confirmed TB, 567 (37%) were women. Women had a lower risk of high mycobacterial burden (smear grade ≥ 2 and/or time to detection < 7 days) with an adjusted OR of 0.70 (95% CI, 0.56-0.87). Among the 744 participants who were followed up prospectively, 261 (35%) were women. Women had a lower risk of unfavorable treatment outcomes (adjusted incidence risk ratio, 0.60; 95% CI, 0.43-0.85), mostly because recurrence was lower (adjusted incidence risk ratio, 0.45; 95% CI, 0.23-0.86). Isoniazid (but not rifampicin and pyrazinamide) maximum concentration and area under the curve were significantly higher among women (P < .01) than men. Among women, unfavorable outcomes were more likely among those with cavitary disease, but among men, increased risk of unfavorable outcomes was associated with alcohol use, higher BMI, and lower glycated hemoglobin level. Interpretation: Women present with lower mycobacterial burden, achieve higher TB drug exposure, and are less likely to have unfavorable treatment outcomes than men. Strategies to improve TB treatment success should take into account sex differences in risk factors for unfavorable outcomes. (Copyright © 2022 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu